CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings (NTHI) announced that Executive Chairman & President Amir Heshmatpour will participate in a live interview with Kenny Polcari on YouTube.com/@Floorstocks on July 24, 2025, at 11:00 a.m. ET.
The interview follows NeOnc's recent execution of a Sub-License Agreement with NuroCure, its Abu Dhabi subsidiary, marking progress toward a $50 million strategic partnership with Quazar Investment covering the UAE, GCC, and MENA regions. The company was also recently included in the Russell Microcap Index.
NeOnc is advancing two key therapeutics, NEO100™ and NEO212™, currently in Phase II clinical trials with FDA Fast-Track and IND status. These drug candidates, developed through the company's NEO™ platform, target brain and central nervous system cancers with patent protection until 2038.
NeOnc Technologies Holdings (NTHI) ha annunciato che il Presidente Esecutivo Amir Heshmatpour parteciperà a un'intervista in diretta con Kenny Polcari su YouTube.com/@Floorstocks il 24 luglio 2025 alle 11:00 ET.
L'intervista segue la recente firma da parte di NeOnc di un Accordo di Sub-licenza con NuroCure, sua filiale ad Abu Dhabi, segnando un progresso verso una partnership strategica da 50 milioni di dollari con Quazar Investment che copre gli Emirati Arabi Uniti, il GCC e la regione MENA. La società è stata inoltre recentemente inclusa nel Russell Microcap Index.
NeOnc sta sviluppando due terapie chiave, NEO100™ e NEO212™, attualmente in studi clinici di Fase II con status Fast-Track FDA e IND. Questi candidati farmaci, sviluppati tramite la piattaforma NEO™ dell’azienda, sono destinati a trattare tumori del cervello e del sistema nervoso centrale e godono di protezione brevettuale fino al 2038.
NeOnc Technologies Holdings (NTHI) anunció que el Presidente Ejecutivo Amir Heshmatpour participará en una entrevista en vivo con Kenny Polcari en YouTube.com/@Floorstocks el 24 de julio de 2025 a las 11:00 a.m. ET.
La entrevista sigue a la reciente firma de un Acuerdo de Sub-licencia entre NeOnc y NuroCure, su subsidiaria en Abu Dhabi, marcando un avance hacia una asociación estratégica de 50 millones de dólares con Quazar Investment que cubre los EAU, el GCC y la región MENA. La compañía también fue recientemente incluida en el Russell Microcap Index.
NeOnc está avanzando con dos terapias clave, NEO100™ y NEO212™, actualmente en ensayos clínicos de Fase II con estatus Fast-Track de la FDA y IND. Estos candidatos a fármacos, desarrollados a través de la plataforma NEO™ de la compañía, están dirigidos a tratar cánceres del cerebro y del sistema nervioso central con protección de patente hasta 2038.
NeOnc Technologies Holdings (NTHI)는 Amir Heshmatpour 집행 회장 겸 사장이 2025년 7월 24일 오전 11시(동부 시간) YouTube.com/@Floorstocks에서 Kenny Polcari와 라이브 인터뷰에 참여할 것이라고 발표했습니다.
이번 인터뷰는 NeOnc가 아부다비 자회사인 NuroCure와 서브 라이선스 계약을 최근 체결한 데 따른 것으로, UAE, GCC 및 MENA 지역을 포함하는 5천만 달러 규모의 Quazar Investment와의 전략적 파트너십에 진전을 의미합니다. 회사는 최근 러셀 마이크로캡 지수(Russell Microcap Index)에도 포함되었습니다.
NeOnc는 현재 FDA 패스트트랙 및 IND 상태로 2상 임상시험 중인 두 가지 주요 치료제 NEO100™ 및 NEO212™를 개발 중입니다. 이 약물 후보들은 회사의 NEO™ 플랫폼을 통해 개발되었으며, 뇌 및 중추신경계 암을 대상으로 하며 2038년까지 특허 보호를 받고 있습니다.
NeOnc Technologies Holdings (NTHI) a annoncé que le Président exécutif Amir Heshmatpour participera à une interview en direct avec Kenny Polcari sur YouTube.com/@Floorstocks le 24 juillet 2025 à 11h00 ET.
L'interview fait suite à l'exécution récente par NeOnc d'un accord de sous-licence avec NuroCure, sa filiale à Abou Dhabi, marquant une avancée vers un partenariat stratégique de 50 millions de dollars avec Quazar Investment couvrant les Émirats arabes unis, le GCC et la région MENA. La société a également été récemment incluse dans le Russell Microcap Index.
NeOnc fait progresser deux thérapeutiques clés, NEO100™ et NEO212™, actuellement en essais cliniques de phase II avec un statut Fast-Track FDA et IND. Ces candidats médicaments, développés via la plateforme NEO™ de la société, ciblent les cancers du cerveau et du système nerveux central avec une protection par brevet jusqu'en 2038.
NeOnc Technologies Holdings (NTHI) gab bekannt, dass der Executive Chairman & President Amir Heshmatpour am 24. Juli 2025 um 11:00 Uhr ET an einem Live-Interview mit Kenny Polcari auf YouTube.com/@Floorstocks teilnehmen wird.
Das Interview folgt auf die kürzliche Unterzeichnung eines Unterlizenzvertrags zwischen NeOnc und NuroCure, seiner Tochtergesellschaft in Abu Dhabi, was Fortschritte in Richtung einer strategischen Partnerschaft im Wert von 50 Millionen US-Dollar mit Quazar Investment markiert, die die VAE, den GCC und die MENA-Region abdeckt. Das Unternehmen wurde außerdem kürzlich in den Russell Microcap Index aufgenommen.
NeOnc entwickelt zwei wichtige Therapeutika, NEO100™ und NEO212™, die sich derzeit in Phase-II-Studien mit FDA Fast-Track- und IND-Status befinden. Diese Arzneimittelkandidaten, die über die NEO™-Plattform des Unternehmens entwickelt wurden, zielen auf Hirn- und zentrale Nervensystemkrebsarten ab und sind bis 2038 patentgeschützt.
- Strategic $50 million partnership with Quazar Investment in progress
- Inclusion in Russell Microcap Index, potentially improving institutional investment and liquidity
- Two drug candidates (NEO100™ and NEO212™) in Phase II trials with FDA Fast-Track status
- Patent protection extending to 2038 for proprietary technology
- Partnership with Quazar Investment not yet finalized
- Clinical trials still in early phases with no guaranteed success
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:
NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — July 24, 2025 at 11:00 a.m. ET
NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on YouTube.com/@Floorstocks. The interview will air live July 24, 2025 at 11:00 a.m. ET.
The interview comes on the heels of NeOnc’s recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company’s
NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company’s broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity.
“This is an exciting time for NeOnc Technologies as we move closer to closing the
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What is the status of NTHI's partnership with Quazar Investment?
What stage are NeOnc Technologies' (NTHI) clinical trials in?
When will NTHI's Executive Chairman be interviewed on Floorstocks?
How long does NeOnc Technologies' patent protection last?
What is the significance of NTHI joining the Russell Microcap Index?
